{"id":"W4393343265","doi":"10.1007/s00262-024-03654-0","title":"Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Medicine; Adverse effect; Pharmacokinetics; Internal medicine; Maximum tolerated dose; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007225206,0.0002466528,0.0004859415,0.000164402,0.0001729829,0.0002876061,0.0001873289,0.0002020177,0.0006283006],"category_scores_gemma":[0.0005367264,0.00009023495,0.000236789,0.0002900801,0.0002019786,0.0002199766,0.0001733467,0.0004567766,0.0001743241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000480365,"about_ca_system_score_gemma":0.0005638296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006895436,"about_ca_topic_score_gemma":0.001756894,"domain_scores_codex":[0.9998216,0.00006447999,0.00001940321,0.00002948369,0.000038331,0.0000266366],"domain_scores_gemma":[0.999728,0.00008538413,0.00008123561,0.000009250235,0.00002678838,0.00006924886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05712343,0.003480746,0.2546516,0.002481356,0.0006235851,0.001621827,0.0005235414,0.005276911,0.05995721,0.0002522576,0.006833782,0.6071737],"study_design_scores_gemma":[0.03762206,0.1713854,0.70297,0.0004682733,0.001135183,0.009786043,0.000374924,0.006751736,0.02579865,0.0005549715,0.04309272,0.00005996991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855881,0.01225772,0.0002971989,0.0002635246,0.00002299892,0.0001350668,0.0002059872,0.00002086222,0.001208494],"genre_scores_gemma":[0.9953058,0.003254723,0.0004379287,0.0001901473,0.00003133999,0.00005744478,0.0004457355,0.000003004262,0.0002738353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007225206,"threshold_uncertainty_score":0.003821135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009003923693406368,"score_gpt":0.3100422142431986,"score_spread":0.3010382905497923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}